Enoxaparin in ACS

More documents

Recommendations

Info

Disadvantages of UFHo Unpredictable anticoagulant effect• Significant protein binding• Inactivation by platelet factor 4
Superiority ofEnoxaparin over UFHEvidence-basedo DefinitionsAgendao Is UFH w/o disadvantageso High risk combination of anticoagulants inthe management of ACSo SKo Fibrinolyticso IIb/IIIa Inhibitorso When evidence meets real world practice
Page 1 and 2: Enoxaparin in ACSWhen evidence meet
Page 3: o DefinitionsAgendao Is UFH w/o dis
Page 7 and 8: Coronary patency (TIMI flow 2 or 3)
Page 9 and 10: Enoxaparin versus UFH for STEMIOne
Page 11 and 12: No Increase in ICHents% Ev10UFHENOX
Page 13 and 14: New Data from ExTRACT-TIMI 251YEAR
Page 15 and 16: Net Clinical BenefitDeath/MI/Disabl
Page 17 and 18: Summary-23. Net clinical benefit si
Page 19 and 20: Enoxaparin and GP IIb/IIIa inhibito
Page 21 and 22: NICE -3Objectiveso To assess the sa
Page 23 and 24: o DefinitionsAgendao Is UFH w/o dis
Page 25 and 26: Clexane in ACS - My ApproachACSCons
Page 27: Egyptian Guidelines for themanageme

Enoxaparin in ACS

Create successful ePaper yourself

Delete template?

Save as template?